Vestcor Inc Acquires 13,990 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Vestcor Inc boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 540.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,578 shares of the specialty pharmaceutical company’s stock after purchasing an additional 13,990 shares during the period. Vestcor Inc owned about 0.05% of Collegium Pharmaceutical worth $475,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period. Empowered Funds LLC bought a new stake in Collegium Pharmaceutical during the third quarter valued at $4,693,000. Massachusetts Financial Services Co. MA boosted its position in Collegium Pharmaceutical by 17.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after acquiring an additional 116,327 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter valued at $2,432,000.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on COLL. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Finally, Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Up 1.2 %

Collegium Pharmaceutical stock opened at $29.46 on Monday. The firm has a 50 day simple moving average of $30.85 and a 200 day simple moving average of $32.93. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29. The firm has a market capitalization of $927.58 million, a price-to-earnings ratio of 12.70 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. On average, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,961 shares of company stock worth $3,146,634. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.